ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
1.720
-0.070 (-3.91%)
Oct 29, 2024, 4:00 PM EDT - Market closed
ProKidney Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
163
Market Cap
216.81M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.77B |
Lifecore Biomedical | 128.44M |
Fulcrum Therapeutics | 81.63M |
Nanobiotix | 45.22M |
MacroGenics | 41.02M |
PROK News
- 15 days ago - ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 - GlobeNewsWire
- 20 days ago - ProKidney to Participate in the UBS Virtual Organ Restoration Day - GlobeNewsWire
- 2 months ago - ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S. - GlobeNewsWire
- 2 months ago - ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - ProKidney Reports Business Updates and Second Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering - GlobeNewsWire
- 5 months ago - ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering - GlobeNewsWire
- 5 months ago - ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates - GlobeNewsWire